NCT06980155View on ClinicalTrials.gov

XP-005 Personalized Vaccine Alone or in Combination With Toripalimab for the Prevention of Relapse After Remission in Acute Myeloid Leukemia

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

May 30, 2025

Primary Completion Date

January 30, 2027

Study Completion Date

August 30, 2028

Conditions
Acute Myeloid Leukemia
Interventions
BIOLOGICAL

Personalized neoantigen tumor vaccine

Neoantigen tumor vaccine

BIOLOGICAL

PD-1 inhibitor

Toripalimab

Trial Locations (1)

Unknown

RECRUITING

Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai

All Listed Sponsors
collaborator

Shanghai Xinpu BioTechnology Company Limited

UNKNOWN

lead

Shanghai Jiao Tong University School of Medicine

OTHER